Pharmaceuticals

  • |

    Tiny Tweak, New Monopoly: Evergreening Shouldn’t Mean a Bigger Bill

    ByJustin Jest

    I’m not saying the billion-dollar backroom worships a stopwatch, but the patent expires and—boom—“innovation” shows up as an extended-release, a new coating, or a combo pill. Same original drug, new paperwork, new dose, with that fresh little seal slapped on like it’s a brand-new invention. Not every reformulation is a real breakthrough; sometimes it’s just the legal version of swapping a street sign and calling it “progress.”

    When competition waits, Medicare keeps paying while the price clock does a victory lap under a new nameplate. A small change shouldn’t mean a bigger bill—yet the system treats “tiny tweak” like it’s the next chapter in monopoly fanfic, just with higher invoices.

  • |

    The Medicare Marathon: Sidestepping the Corporate Hurdles

    ByHarlan Quill

    Medicare these days resembles a marathon where seniors are the athletes, yet the finish line keeps moving at the whim of corporate sponsors. The noble promise of Medicare comes with a side order of boardroom influence—almost as if healthcare policies were auctioned off to the highest bidder behind closed doors.

    If navigating Medicare were like running a race, the water stations would be staffed by pharmaceutical execs charging for each drop. Meanwhile, seniors jog along, dodging hurdles in the form of overpriced prescriptions and benefit cutbacks. The real prize seems reserved for those in the luxury boxes, watching the spectacle unfold without breaking a sweat.

End of content

End of content